Dissociation of plasma oxyntomodulin levels from anthropometric measures and metabolic markers in women with polycystic ovary syndrome
Authors:
- Rachel C. DamascenoRDRachel C. Damasceno
- Flávia R. OliveiraFOFlávia R. Oliveira
- Ana Lúcia CândidoACAna Lúcia Cândido
- Karina B. GomesKGKarina B. Gomes
- Mariana F. BizziMBMariana F. Bizzi
- Ana Luiza Lunardi RochaARAna Luiza Lunardi Rocha
- Rosana C. AzevedoRARosana C. Azevedo
- Fábio V. ComimFCFábio V. Comim
- Fernando M. ReisFRFernando M. Reis
Open Access
- 1 January 2025
- journal article
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 69 (3) , 1-5
Abstract
Introduction: Oxyntomodulin (OXM) is a polypeptide hormone of the incretin family, which binds to the glucagon-like peptide 1 receptor, contributing to a reduction in caloric intake, an increase in energy expenditure, and weight loss in obese individuals. Polycystic ovary syndrome (PCOS) is a multifactorial condition characterized by reproductive and metabolic dysfunctions, with a high prevalence among overweight and obese women. This study aimed to investigate the correlation between clinical, anthropometric, endocrine, and metabolic variables and plasma OXM levels in [...] ABSTRACT Introduction: Oxyntomodulin (OXM) is a polypeptide hormone of the incretin family, which binds to the glucagon-like peptide 1 receptor, contributing to a reduction in caloric intake, an increase in energy expenditure, and weight loss in obese individuals. Polycystic ovary syndrome (PCOS) is a multifactorial condition characterized by reproductive and metabolic dysfunctions, with a high prevalence among overweight and obese women. This study aimed to investigate the correlation between clinical, anthropometric, endocrine, and metabolic variables and plasma OXM levels inKeywords
This publication has 22 references indexed in Scilit:
- Recent advances in the understanding and management of polycystic ovary syndromeF1000Research, 2019
- Oxyntomodulin analogue increases energy expenditure via the glucagon receptorPeptides, 2018
- Unraveling oxyntomodulin, GLP1's enigmatic brotherJournal of Endocrinology, 2012
- Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in miceDiabetologia, 2010
- Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metforminMetabolism, 2009
- Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm AnalogsEndocrinology, 2008
- Incretin levels in polycystic ovary syndromeEuropean Journal of Endocrinology, 2008
- Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trialInternational Journal of Obesity, 2006
- Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese SubjectsDiabetes, 2005
- Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic SubjectsDiabetes Care, 2001